Regeneron Pharmaceuticals has announced that the FDA has approved Eylea (aflibercept) injection for treatment of diabetic macular edema (DME) in the U.S. Eylea now joins Genentech’s Lucentis (ramabizumab) as a treatment for DME in addition to neovascular (wet) age-related macular degeneration and macular edema after central retinal vein occlusion.
Aflibercept has also been approved for these uses in the European Union, where it is marketed by Bayer Healthcare. They are still awaiting approval for treatment of branch retinal vein occlusion.
More information
